SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...

Pediatric and adult patients experienced noninferior and robust immune responses to RIV4, as well as similar safety profiles.

A group of researchers from Japan's University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center said ...

A group of researchers says delayed treatment of a type of bird flu now spreading on dairy farms in the United States may ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...